These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34400948)

  • 1. The Radiolabeled HER3 Targeting Molecules for Tumor Imaging.
    Molavipordanjani S; Hosseinimehr SJ
    Iran J Pharm Res; 2021; 20(1):141-152. PubMed ID: 34400948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
    Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
    Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
    Lyu H; Han A; Polsdofer E; Liu S; Liu B
    Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
    Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER3 signaling and targeted therapy in cancer.
    Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
    Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer.
    Arienti C; Pignatta S; Tesei A
    Front Oncol; 2019; 9():1308. PubMed ID: 31850207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER3/ErbB3, an emerging cancer therapeutic target.
    Zhang N; Chang Y; Rios A; An Z
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.
    Liu X; Liu S; Lyu H; Riker AI; Zhang Y; Liu B
    Biol Proced Online; 2019; 21():5. PubMed ID: 30930695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER family in cancer progression: From discovery to 2020 and beyond.
    Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM
    Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
    Jacob W; James I; Hasmann M; Weisser M
    Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of small molecules targeting the pseudokinase Her3.
    Lim SM; Xie T; Westover KD; Ficarro SB; Tae HS; Gurbani D; Sim T; Marto JA; Jänne PA; Crews CM; Gray NS
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3382-9. PubMed ID: 26094118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
    Dey N; Williams C; Leyland-Jones B; De P
    Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
    Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
    Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.